alexa Regenerative Medicine-From Promise To Patient | 72601
ISSN: 2157-7552

Journal of Tissue Science & Engineering
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Joint Conference:3rd International Conference & Exhibition on TISSUE PRESERVATION AND BIOBANKING & 6th International Conference onTISSUE ENGINEERING AND REGENERATIVE MEDICINE

Debra Aub Webster
Cardinal Health Regulatory Sciences, USA
ScientificTracks Abstracts: J Tissue Sci Eng
DOI: 10.4172/2157-7552-C1-033
Abstract
The expansion in the use of human cells and tissues from their functions in practice of medicine, for repair or replacement, to their use as a manufactured product intended to treat an indication or condition has led to increased regulatory oversight by FDA. Under the authority of Section 361 of the PHS Act, FDA introduced a comprehensive regulatory program in 1997 for human cells, tissues, and cellular and tissue-based products (HCT/Ps). This consolidated regulatory approach is tiered and risk-based to allow for less regulatory evaluation of products determined to present a minimal risk to patient safety. In 2005, this regulatory program was implemented in rules codified under 21 CFR Section 1271. Under these rules, some HCT/Ps are defined as biological products, requiring market clearance. The potential regulatory pathways for HCT/Pderived technologies is often complex, and understanding these regulatory pathways and the definitions surrounding them is critical to successful product development. Navigating the regulatory path, from scientific discovery to initiation of clinical investigations is challenging. These challenges include determination of the appropriate regulatory pathway and understanding the requirements regarding demonstration of safety and efficacy and identification of appropriate quality attributes regarding product safety, quality, and potency. FDA has issued numerous guidance documents and offers several expedited approval pathways in order to bring effective discoveries safely forward, to benefit patients. Successful strategies for achieving this goal include identifying critical information gaps with respect to the appropriate regulatory pathway; informed clinical, nonclinical, and quality development plans; maintaining a Target Product Profile; and successful interaction with the appropriate review division within FDA.
Biography

Debra Aub Webster has over 20 years of experience in Pharmaceutical Research and the Regulatory Environment. She started her regulatory career with the US FDA as Reviewing Toxicologist/Pharmacologist. As a Principal Scientist in Regulatory Affairs and Product Development with Cardinal Health Regulatory Sciences, she is the Project Lead for biologic and regenerative medicine product development programs. In this capacity, she provides guidance on clinical, nonclinical, and regulatory aspects of strategic product development, author regulatory documents, and acts as the regulatory representative for sponsors in interactions with FDA.

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

bornova escort

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

https://www.gaziantepescort.info

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7